Opinion statement Small cell lung cancer is a rapidly proliferating, biologically aggressive
form of lung cancer that has a short survival without treatment. Chemotherapy is the …

Objectives: Topotecan, a potent inhibitor of the enzyme topoisomerase I, has shown an
interesting activity against several types of solid tumors, most notably small cell lung cancer …

Standard chemotherapy regimens in non-small-cell lung cancer (NSCLC) are platinum-
based (cisplatin, carboplatin), with inherent, well-known antitumor activity and toxicity …

Locally advanced non–small-cell lung cancer (NSCLC) represents 30%–40% of all
pulmonary malignancies. Despite the fact that the disease is confined to the chest, most …

Inhibition of topoisomerase I by topotecan results in a compensatory increase in
topoisomerase II levels associated with increased in vitro sensitivity of tumors to etoposide …

Abstract Topotecan (HYCAMTIN®; GlaxoSmithKline, Brentford, Middlesex, UK) is a novel
topoisomerase I inhibitor with potentially broad applicability in the treatment of solid and …

Small-cell lung cancer (SCLC) is an aggressive malignancy, and only a minority of patients
survive 2 years. Although this cancer is sensitive to both chemotherapy and radiotherapy …

Lung cancer continues to be the leading cause of cancer-related death in the United States.
Small-cell lung cancer constitutes 15%–20% of all cases of lung cancer. It is a …